Core Viewpoint - A shareholder has filed a securities class action lawsuit against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its G7 continuous glucose monitoring system, affecting investors who purchased securities between January 8, 2024, and September 17, 2025 [1][3]. Group 1 - The lawsuit claims that the defendants made false statements about the reliability and enhancements of the Dexcom G7 device, as well as the company's manufacturing capabilities [3]. - Investors who acquired DexCom securities during the specified period are encouraged to consider their legal rights and options regarding the class action [2][4]. - The deadline to file as a lead plaintiff in the class action is December 26, 2025, with no fees or expenses required from shareholders [4]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, indicating a strong track record in this area [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, affecting investors who purchased securities between January 8, 2024, and September 17, 2025 [1][2]. Group 1 - The lawsuit claims that the defendants made false statements about the reliability and enhancements of the Dexcom G7 system, as well as the company's manufacturing capabilities [2]. - Investors who wish to serve as lead plaintiffs must file by December 26, 2025, but participation in any recovery does not require serving as lead plaintiff [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4].